期刊文献+

清洁间歇导尿联合托特罗定治疗瓣膜膀胱综合征的疗效分析

Analysis of the Efficacy of Clean Intermittent Catheterization Combined with Tolterodine in the Treatment of Valvular Bladder Syndrome
下载PDF
导出
摘要 目的:探讨早期清洁间歇导尿(Clean intermittent catheterization, CIC)联合托特罗定治疗膀胱瓣膜综合征的疗效,为后尿道瓣膜术后改善膀胱功能提供参考。方法:回顾性分析我中心行膀胱镜后尿道瓣膜切除术后患儿36例。术后首次随访尿动力学提示小膀胱容量或/和膀胱顺应性差或/和逼尿肌不稳定和/或诊断为膀胱过度活动,并且有残余尿。按照既往治疗方式分为CIC联合托特罗定组(n = 20)和CIC组(n = 16)。在治疗后1个月随访两组尿动力检查、尿路造影。结果:治疗后1月,尿动力学中,CIC联合托特罗定组逼尿肌不稳定率及膀胱顺应性差发生率低于CIC组(p 0.05)。结论:CIC联合托特罗定对后尿道瓣膜切除术后患儿可改善膀胱功能,短期效果明显。 Objective: To investigate the efficacy of early clean intermittent catheterization (CIC) combined with tolterodine in the treatment of bladder valve syndrome and to provide a reference for improving bladder function after posterior urethral valvulotomy. Methods: A retrospective analysis of 36 children who underwent cystoscopic posterior urethral valve resection at our centre. The first postoperative follow-up urodynamics suggested overactive bladder and/or small bladder capacity or/and poor bladder compliance or/and instability of the detrusor muscle, and residual urine. The CIC combined with tolterodine group (n = 20) and the CIC group (n = 16) were divided according to previous treatment. Both groups were followed up at 1 month after treatment with urodynamic tests and urography. Results: 1 month post-treatment, in urodynamics, the rates of forceps instability and poor bladder compliance were lower in the CIC combined with tolterodine group than in the CIC group (p 0.05). Conclusion: CIC combined with tolterodine improves bladder function in children after posterior urethral valvulotomy with significant short-term results.
出处 《临床医学进展》 2022年第3期1748-1757,共10页 Advances in Clinical Medicine
  • 相关文献

参考文献4

二级参考文献15

  • 1邱颖,谢向辉,孙宁,张潍平,田军,李明磊,宋宏程,李宁,屈彦超,黄澄如.后尿道瓣膜切除术后尿动力学研究[J].临床小儿外科杂志,2010,9(5):330-333. 被引量:4
  • 2唐达星,孙革.托特罗定与颠茄合剂治疗儿童逼尿肌过度活跃症疗效比较[J].中华小儿外科杂志,2007,28(7):389-390. 被引量:4
  • 3Neveus T, Von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society[J]. J Urol, 2006, 176( 1 ) : 314-324.
  • 4Kajiwara M, Inoue K, Kato M, Usui A, Kufihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study[J], lnt J Urol, 2006, 13( 1 ) : 36-41.
  • 5Hommaa Y, Yoshidab M, Sekic N, Yokoyamad O, Kakizakie H, Gotohf M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score[ J]. Urology, 2006, 68(2) : 318-323.
  • 6Dmtz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of toherodine compared to oxybutynin and placebo in patients with overactive bladder[ J]. Int Urogynecol J Pelvic Floor Dysfunct,1999,10(5 ) : 283-289.
  • 7Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Toherodine--a new bladder-selective antimuscarinic agent [ J ]. Eur J Pharmacol, 1997,327 ( 2 -3 ) : 195-207.
  • 8Raes A, Hoebeke P, Segaert I, Van Laecke E, Dehoome J, Vande Walle J. Retrospective analysis of efficacy and tolerability of toherodine in children with overactive bladder [ J ]. Eur Urol, 2004, 45 (2) : 240-244.
  • 9Hjalmas K, Hellstrom AL, Mogren K, Lackgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine[J]. BJU lnt, 2001, 87(6) : 569-574.
  • 10Nijman R, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials[J]. J Urol, 2005, 173(4) : 1334-1339.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部